This story was originally published June 10.
The Center for Translational Oncology and Immunology, TrOn, a new research institute affiliated with the University of Mainz in Germany, has received an Illumina HiSeq 2000 sequencer, the institute said last week.
According to Ugur Sahin, the center's director and a professor of experimental oncology at the University of Mainz, the new instrument will allow the researchers to analyze the genomes of tumor and immune cells to better understand "the interplay of cancer treatment and the immune system" and to develop customized therapies.
To analyze the sequence data, the center will collaborate with the Mainz University Center of Data Processing, ZDV.
TrOn, which was launched in February, is focused on developing "innovative diagnostics and therapeutics" for cancer patients, according to its website.
The not-for-profit university spinout will initially have 50 employees and has an estimated budget of €30 million ($36 million) over its first five years. Almost €20 million of that will come from private and public funding, while about a third will come from the ministry of science of the state of Rhineland-Palatinate.
Eventually, the institute plans to have 90 to 120 employees and fund itself through service work and projects.